Valencia, CA – According to filings with the U.S. Securities and Exchange Commission, Nusano is raising $69,999,985.00 in new funding. Sources indicate as part of senior management Chief Executive Officer, Brian Mckernan played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.

About Nusano
Innovation demands vision, but even the brightest ideas in fields like nuclear medicine are constrained by the high cost and limited range of radioisotopes. Our transformative process pushes past these barriers by radically increasing flexibly and boosting yields by orders of magnitude bringing stability to nuclear medicine, unleashing the true potential of theranostics, and freeing the creativity that will drive tomorrows therapies. By turning scarcity into abundance, Nusano is replacing what’s plausible with what’s possible. Developer of a high current ion source and linear accelerator intended to remove the current limitations of radioisotopes manufacturing for medical application and innovation. The company offers a broad range of diagnostic and therapeutic radioisotopes which are produced uranium-free, thereby helping the market to develop radiopharmaceuticals for personalized cancer therapies at comparatively lower costs.

To learn more about Nusano, visit http://www.nusano.com/

Contact:
Brian Mckernan, Chief Executive Officer
424-270-9600
https://www.linkedin.com/in/brian-mckernan-0546617/

SOURCE: http://www.intelligence360.io
Copyright (c) 2021 SI360 Inc. All rights reserved